PTU - Polskie Towarzystwo Urologiczne
list of articles:

INTRAVESICAL INSTILLATION BCG IN TREATMENT OF SUPERFICIAL TUMORS CLINIC OF UROLOGY MILITARY MEDICAL ACADEMY ŁÓD¬
Article published in Urologia Polska 1995/48/3.

authors

Piotr Kaczmarek, Eugeniusz Mięko¶, Jan Kaczmarek
Z Kliniki Urologii Instytutu Chirurgii WAM w Łodzi
Kierownik Kliniki: prof. dr hab. med. E. Mięko¶

summary

The authors present the results of two year obserwation of 56 patients with superficial bladder
tumors. After electrosection of a tumor, 36 patiens (64,28%) were given installations BCG, but 20
35,71%
ment). During the further observation of the patients, it come out that in the grup I BCG there was no
recurrent tumor with 21 (58,47%) patients Comparing to only 4 (20%) patients in the grup II. The
results were statistically proved.

references

  1. 1. Bettex Ganlland M., Studer U.E., Walz A.: Neutropilactiwating peptide-1 (interleukin-8 detec-
  2. tion) in human urine during acute bladder inflammation caused by transurethral resection of superfi-
  3. cial cancer and bacillus Calmette - Guerin administration. Eur.Urol., 1991, 19(2), 171 - 5. ? 2.
  4. BohleA., GardesJ., UlmerA.J.; Effects of local BCG therapy in patients with bladder carcinoma on
  5. immunocom petent cells of the bladder wall. J. Urol., 1990 Jul, 144(1), 53-8. ? 3. Chopin D.,
  6. Hoznek A., Colombel M.: Results of treatment of superficial vesical tumors by transurethral resection
  7. alone and transurethral resection followed by on intra- vesical instillation of Calmette Guerin bacil-
  8. lus. Ann. Urol. Paris, 1991, 24(5), 435 - 40. ? 4. Debruyne F. M. J., Witjas J. A.: The treatment of
  9. supperficial bladder tumors and carcinoma in situ with intravesical instillations of Bacillus Calmet-
  10. te - Guerin. Interface, 1990. ? 5. de Kernion J.B.: Intravesical therapy with BCG. Immuno therapy
  11. of Urological. Tumours Society Internationale D' Urologie, 1990, 113 - 117. ? 6. Jakse G:. BCG for
  12. carcinoma in situ. Eur. Urol., 1992, 21 ( supp 2 ), 30 - 34. ? 7. Lamm D.L.: Optimal BCG treatment
  13. of superficial bladder cancer as defined by American Trials. Eur. Urol., 1992, 21, 12 - 16. 8. Lamm
  14. D.L.: Open questions on mechanismus BCG. Eur. Urol., 1992, 21, 28 - 29. ? 9. Leong A.S., Wanna-
  15. krairot P., Jose J:. Bacillus Calmette- Guerin treated superficial bladder cancer, corelation of mor-
  16. phology with immunophenotyping. J. Pathol., 1990, Sep., 162 (1), 35 - 41. ? 10. Mięko¶ E:. Evalu-
  17. ation of urinary bladder tumor growth with transurethral ultrasonography. 6th Congress of the Euro-
  18. pean Federatione of Societies ?Euroson- 87", Helsinki 1987, 131. ? 11. Mikkelsen D. J., Ratlif
  19. T.L.: Mechanisms of action of in- travesical BCG for bladder cancer. Cancer. Treat. Res., 1989, 46,
  20. 195 - 211. ? 12. Oda H., Sęki N., Nabeshima S:. Comperative clinical trial of UFT medication and
  21. interavesical BCG in the recurrens of superficial bladder cancer. Study group of UFT and BCG
  22. adjuyant therapy for bladder cancer. Gan. To. Kagaku. Ryoho., 1990, Oct., 17 (10), 2051-5. ? 13.
  23. RaliffT.: Role of the immunorespons in BCG for bladder cancer. Eur. Urol., 1992, 21 (supp 2), 17-
  24. 21. ? 14. Schmidt J.D.: Interavesical BCG for superficial bladder cancer comporison of prymary
  25. tumour to development of progressive disease elsewhere. Immurnotherapy of urological tumours,
  26. Society Internationale D'Urologie, 1990, 53-8. ? 15.Yabusaki N., KamatsuH., Tag K.: Intravesical
  27. instillation of bacillus Calmette - Guerin in the treatment of superficial montenance instillations of
  28. BCG. Nippon Hinyokika Gakkai Zasshi, 1990, Feb., 82 (2), 290-6. ? 16. Yamamolo T., Haggiwara
  29. M, Nakazano M:. Intervesical bacillus Calmette - Guerin in the treatment of superficial bladder
  30. cancer. Prospects randomized study for prophilactic effeet. Nippozi Hinyokika Gakkai Zsshi, 1990,
  31. Jul., 81 (7), 997-1001. ? 17. Zieliński J:. Onkologia urologiczna, PZWL, 1986.